Phase 0 clinical trials as a strategy to accelerate the discovery of new targets against cancer

Authors

  • Maykel Pérez Machín Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba
  • Rayza Méndez Triana Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba
  • Migdalia Rodríguez Rivas Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba

Keywords:

controlled clinical trial, neoplasms/drug therapy

Downloads

Download data is not yet available.

Author Biographies

Maykel Pérez Machín, Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba

Licenciado en Ciencias Farmacéuticas. Máster en Medicina Bioenergética y Natural. Profesor Auxiliar de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Rayza Méndez Triana, Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba

Licenciada en Ciencias Farmacéuticas. Máster en Bioquímica General. Profesora Asistente de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Migdalia Rodríguez Rivas, Universidad de Ciencias Médicas de “Dr. Serafín Ruiz de Zárate Ruiz”, Santa Clara, Villa Clara, Cuba

Especialista de I y II Grado en Farmacología. Máster en Medicina Bioenergética y Natural. Profesora Auxiliar de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Downloads

How to Cite

1.
Pérez Machín M, Méndez Triana R, Rodríguez Rivas M. Phase 0 clinical trials as a strategy to accelerate the discovery of new targets against cancer. Acta Méd Centro [Internet]. 2011 Jan. 13 [cited 2025 Jun. 30];5(1):106-9. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/560

Issue

Vol. 5 No. 1 (2011): January-March. Special Issue of Obstetrics and Gynecology

Section

Oncology

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).